Vericel Corporation Q4 2025 Earnings Call Summary

Record Q4 revenue growth of 23% was primarily volume-driven, supported by the highest number of MACI implants and implanting surgeons since the product's 2017 launch. The MACI Arthro technique has successfully accelerated growth in the small condyle defect segment, which historically lagged but became a top growth driver in 2025. Surgeons trained in MACI Arthro demonstrate higher biopsy and implant growth rates, with even higher conversion rates observed once they complete their first Arthro case. M ...